- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00771199
An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain
September 16, 2014 updated by: Janssen-Cilag Ltd.
An Open-label, Multicenter Study to Evaluate the Safety/Tolerability and Clinical Utility of Low-dose TTS-Fentanyl D-TRANS in Taiwan Patients With Cancer Pain
The purpose of this study is to evaluate safety/tolerability and clinical utility of low-dose transdermal therapeutic system (TTS [medicated adhesive pad that is placed on the skin to deliver a timed-release dose of medication through the skin into the bloodstream]) - fentanyl in Taiwan participants with cancer pain.
Secondly, to demonstrate the dropout rate that will be decreased by initiating therapy with12 microgram per hour (mcg/hr) instead of with 25 mcg/h.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open-label (all people know the identity of the intervention), multi-center (when more than one hospital or medical school team work on a medical research study), single-arm, non-randomized study to evaluate the efficacy and safety of low-dose TTS-fentanyl in Taiwan participants with cancer pain.
Eligible participants will be enrolled and scheduled to return at Day 0, 7, 14 and 28.
Participants will receive TTS-fentanyl for 28 days at a starting dose of 12 micrograms per hour (mcg/h) (one patch).
Dose of fentanyl can increased or decreased as per Investigator's discretion to maintain participant's pain score at 2 or less on the Brief Pain Inventory (BPI) question 6 (that tells how much pain you have right now).
Safety will primarily be evaluated by measuring participant's dropout rate due to adverse events.
Participants' safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants diagnosed with cancer; histologically (examination of tissue specimens under a microscope) confirmed malignancy (term for diseases in which abnormal cells divide without control and can invade nearby tissues)
- Participants who are able to communicate effectively with study personnel
- Participants who have intolerable cancer pain (pain score greater than or equal to [>=] 4)
- Participants who have an estimated life expectancy of at least 30 days
- Participants who have given written dated informed consent to participate in the study
Exclusion Criteria:
- Participants who have already received regular treatment with an strong opioid (morphine-like synthetic narcotic that produces the same effects as drugs derived from the opium poppy [opiates]), for their pain before entering the study
- Participants who have already received tramadol (a narcotic-like pain reliever used to treat moderate to severe pain) treatment over 200 milligram (mg) for their pain before entering the study
- Participants with significant abnormalities in hepatic or renal function which would, in the opinion of the Investigator, prevent the participants involvement in the study
- Participants with significant clinical abnormalities in central nervous system (CNS), respiratory or cardiovascular function, which in the investigators judgment prevents participation in the study
- Pregnant or lactating females or females of child bearing potential not currently practicing documented, adequate contraception
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Transdermal Therapeutic System (TTS)-Fentanyl
|
Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days.
Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Dropped From Study due to Adverse Events
Time Frame: Day 0 up to Day 28
|
An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical product.
An adverse event does not necessarily have a causal relationship with the treatment.
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Percentage of participants who will be prematurely withdrawn from the study due to any adverse events will be reported.
|
Day 0 up to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brief Pain Inventory (BPI) Score (Question 6)
Time Frame: Day 0, Day 7, Day 14 and Day 28
|
The BPI question number 6 describes pain severity, will be measured by the daily pain diary on numeric rating scale (NRS), ranging from 1 to 10; where 0 signifies no pain and 10 signifies extreme pain.
|
Day 0, Day 7, Day 14 and Day 28
|
BPI Score (Question 9) - Quality of Life (QOL)
Time Frame: Day 0, Day 7, Day 14 and Day 28
|
Participant's quality of life (QOL) will be assessed by BPI question number 9 (items 9a to 9g), which describes "how during the past 24 hours pain has interfered with participants general activity, mood, walking ability, normal work, relation with other people, sleep, enjoyment of life".
Each item will be measured on NRS, ranges from 1 to 10 where 0 signifies does not interfere and 10 signifies completely interferes.
Total score is the average of scores of all items and ranges from 0 to 10, where higher scores signifies higher pain/interference.
|
Day 0, Day 7, Day 14 and Day 28
|
Average Daily Dose and Final Dose of Transdermal Therapeutic System (TTS)-fentanyl
Time Frame: Day 0 up to Day 28
|
The TTS-fentanyl dosage is only increased in consultation with the treating physician and according to the participant's analgesic requirements, with the intention of maintaining his/ her pain score at 2 or less on the BPI question 6.
|
Day 0 up to Day 28
|
Investigator's Global Assessment Scale Score
Time Frame: Day 0 and Day 28
|
Investigator will complete a global assessment of the participants treatment with respect to pain control using 4-point scale, where 1 signifies poor, 2 signifies fair, 3 signifies good, 4 signifies very good.
|
Day 0 and Day 28
|
Percentage of Participants With Treatment Satisfaction
Time Frame: Day 0 and Day 28
|
Participants will rate their assessment of treatment satisfaction, using 4-point scale where 1 signifies poor, 2 signifies fair, 3 signifies good and 4 signifies very good.
|
Day 0 and Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (ACTUAL)
November 1, 2008
Study Completion (ACTUAL)
November 1, 2008
Study Registration Dates
First Submitted
October 10, 2008
First Submitted That Met QC Criteria
October 10, 2008
First Posted (ESTIMATE)
October 13, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
September 17, 2014
Last Update Submitted That Met QC Criteria
September 16, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR014602
- FENPAI4054 (OTHER: Janssen-Cilag Ltd)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer, Pain
-
Kyowa Kirin Co., Ltd.Completed
-
University Hospital, Basel, SwitzerlandTerminatedCancer: Breakthrough Pain | Cancer: Extreme Pain on MovementSwitzerland
-
University of UtahCompletedCancer-associated PainUnited States
-
University of JordanCompleted
-
Laboratoires Bouchara-RecordatiUnknown
-
University of PittsburghCompletedMetastatic Cancer | Invasive Cancer | Pain, CancerUnited States
-
Wex Pharmaceuticals Inc.Completed
-
Sorrento Therapeutics, Inc.WithdrawnPain, Intractable | Pain Cancer
-
Kyowa Kirin Co., Ltd.Completed
Clinical Trials on Transdermal Therapeutic System (TTS)-Fentanyl
-
Alza Corporation, DE, USACompleted
-
Alza Corporation, DE, USACompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
South Egypt Cancer InstituteUnknownBreast Cancer FemaleEgypt
-
Preceptis Medical, Inc.CompletedOtitis Media | Ear InfectionUnited States
-
Janssen Pharmaceutical K.K.Completed
-
Janssen Korea, Ltd., KoreaCompletedChronic PainKorea, Republic of
-
Janssen Research & Development, LLCCompleted